摘要
目的:观察对60例臀上皮神经炎患者采用超声引导下针刀配合冲击波治疗的临床疗效。方法:回顾性分析在2022年12月到2023年12月期间,60例采用超声引导下针刀配合冲击波治疗臀上皮神经炎的患者。对治疗前、首次疗程后及治疗结束3周后疼痛模拟视觉量表(VAS)评分、日本骨科协会腰部功能评分表(JOA)、超声下臀上皮神经卡压部位横径数值、空腹血清疼痛介质水平进行比较分析,统计临床有效率评定患者的临床疗效。结果:患者疗程结束后3周VAS评分为(2.21 ± 1.25)分,JOA评分为(25 ± 1.58)分,超声下臀上皮神经卡压部位横径数值为(1.39 ± 0.68) mm,疼痛介质水平5-HT为(0.23 ± 0.034) μmol/L、PGE2为(418.35 ± 26.39) ng/L、Cor为(84.85 ± 4.26) ng/mL、ACTH为(37.07 ± 3.26) pg/mL,比治疗前及首个疗程后均有较大改善,临床有效率为91.67%,差异均有统计学意义(P Objective: To observe the clinical effect of ultrasound-guided acupotomy combined with shockwave therapy on 60 patients with gluteal epithelial neuritis. Methods: A retrospective analysis of 60 patients treated with ultrasound-guided acupotomy combined with shockwave therapy for gluteal epithelial neuritis was performed between December 2022 and December 2023. Before treatment, after the first course of treatment and 3 weeks after the end of treatment, the score of pain Analog Visual Scale (VAS), the Japanese Orthopaedic Association Lumbar Function Rating Scale (JOA), the transverse diameter of the hip epithelial nerve compression site under ultrasound, and the level of fasting serum pain mediators were compared and analyzed, and the clinical effective rate was statistically evaluated. Result: The VAS score and JOA score of the patient were (2.21 ± 1.25) and (25 ± 1.58) respectively at 3 weeks after treatment. The transverse diameter of the entrapage site of the gluteal epithelial nerve under ultrasound was (1.39 ± 0.68) mm. Pain mediators were 5-HT (0.23 ± 0.034) μmol/L, PGE2 (418.35 ± 26.39) ng/L, Cor (84.85 ± 4.26) ng/mL, ACTH (37.07 ± 3.26) pg/mL. Compared with before and after the first course of treatment, the clinical effective rate was 91.67%, and the differences were statistically significant (P < 0.05). Conclusion: Ultrasound-guided needle-knife combined with shockwave therapy for gluteal neuritis has the advantages of visualization and precise localization, and is a safe and effective treatment method worthy of clinical promotion.
出处
《临床个性化医学》
2024年第3期780-787,共8页
Journal of Clinical Personalized Medicine
